When cancer is diagnosed, the grade of its malignancy is a central concern for both patients and their physicians. This value is used to determine how intensively and how radically the cancer must be treated. Particularly in the case of prostate cancer, the disease can take widely varying courses in different patients…
Published online Dec. 5 in PLOS ONE, the scientists say the agent, YK-4-279, is the first drug targeted at the chromosomal translocations found in about half of prostate cancer cells. These translocations occur when two normal genes break off from a chromosome and fuse together in a new location. …
In the first study to rigorously address prostate cancer treatment trends by life expectancy in a large, nationally representative sample, UCLA researchers found that more than half of prostate cancer patients 66 years and older have life expectancies of less than10 years, but half of those still were over-treated for their prostate cancer with surgery, radiation or brachytherapy, the implantation of radioactive seeds in the prostate. Randomized controlled studies have suggested that significant differences in survival between watchful waiting — monitoring the cancer closely but not treating it — and aggressive therapies don’t develop until 10 years after treatment. It only makes sense to not treat men expected to die of something else within 10 years…
Marie-Elise Parent and Marie-Claude Rousseau, professors at university’s School of Public Health, and their colleague Andrea Spence, published their findings in the journal Cancer Epidemiology. The results were obtained as part of the Montreal study PROtEuS (Prostate Cancer & Environment Study), in which 3,208 men responded to a questionnaire on, amongst other things, their sex lives…
The only place in the Southeast offering the MRI-US image fusion technique is at the University of Alabama at Birmingham Program for Personalized Prostate Cancer Care. It is estimated that 2014 will see more than 240,000 new cases of prostate cancer, and more than 29,000 deaths from the disease, according to the National Cancer Institute…
The Prostate Cancer Prevention Trial was a randomized, double-blind, placebo-controlled trial which tested the efficacy of finasteride, a drug used for prostate cancer prevention. This study was conducted by SWOG — a cancer research cooperative group that designs and conducts multidisciplinary clinical trials. …
source : http://www.sciencedaily.com/releases/2014/07/140715165931.htm
source : http://www.sciencedaily.com/releases/2014/03/140307084000.htm
source : http://www.sciencedaily.com/releases/2014/01/140129134909.htm
"Men with castration-resistant prostate cancer have abysmal survival rates, typically living an average of two years once hormone therapies fail," says Manish Kohli, M.D., a Mayo Clinic oncologist and principal investigator of the Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study. Dr. Kohli says the poor prognosis for men with this cancer highlights the need for studies like PROMOTE, which seek to match new targeted drugs with the genomic characteristics of individual patients’ tumors. Several new therapies have recently been approved by the FDA for use in treating castration-resistant prostate cancer, offering new hope for men with this disease. …